


# ANTIVIRAL DISCOVERY PIPELINE IN SARS-COV-2 DEVELOPING ANTIVIRALS TO TREAT PERSISTENT INFECTION

**SARA CHERRY**

JOHN W. ECKMAN PROFESSOR OF MEDICAL SCIENCE  
PATHOLOGY AND LABORATORY MEDICINE  
SCIENTIFIC DIRECTOR, HIGH-THROUGHPUT SCREENING CORE  
DIRECTOR, PROGRAM FOR CHEMOGENOMIC DISCOVERY  
LEADER, THERAPEUTICS, INSTITUTE FOR RNA INNOVATION

# ACUTE COVID-19



## UPPER RESPIRATORY INFECTION

- HIGH LOADS
- LOW SYMPTOMS


## LOWER RESPIRATORY INFECTION

- MORE SYMPTOMS
- CAN PROGRESS TO SEVERE


<https://www.sciencedirect.com/science/article/pii/S1074761320302120>

# SARS-COV-2 INFECTIONS....




## Antivirals



## Health Problems post-COVID



# ANTIVIRALS: COMBATING ACUTE INFECTION



DIRECT ACTING ANTIVIRALS  
oBLOCK VIRUS ITSELF

HOST DIRECTED ANTIVIRALS



oTARGET HUMAN PROTEINS

IMMUNOMODULATORS

o BOOST EARLY IMMUNITY


# Antivirals

>20,000 DRUGS SCREENED, VALIDATED ~150 DRUGS




Pyrimidine bio

Purine biosyn




Schultz et al 2022

## NUCLEOSIDE ANALOGS




## NUCLEOSIDE BIOSYNTHESIS




## COMBINATION THERAPIES

SYNERGIES: ORAL COMBINATIONS  
LOWER DOSES, HIGH BARRIER TO RESISTANCE



### ADDITIVITY



### SYNERGY



# AIR-LIQUID INTERFACE CULTURES






# COMBINATION REDUCED TITERS AND INFLAMMATION




Freiman lab

SARS-CoV-2- South Africa

1e5 PFU/mouse






# EARLY RESPONSES DELAYED...





# BOOSTING EARLY IMMUNITY BLOCKS INFECTION


Interferons and STING agonists can block infection



# SARS-COV-2 INFECTIONS....LONG COVID



# WHAT DRIVES CHRONIC SYMPTOMS?



Source: GAO analysis of medical literature. | GAO-22-105666

IS THERE VIRAL ANTIGEN?  
WHERE?

HOW IS INFECTION SIMILAR OR  
DIFFERENT FROM RESPIRATORY TRACT?



- SENSITIVITIES TO THERAPEUTICS
- IMMUNE RESPONSES

GASTROINTESTINAL TRACT?


- HIGH SHEDDING (SEWAGE)
- BIOPSIES
- AUTOPSIES

# PASC: IS THE GUT A VIRAL RESERVOIR?

## AUTOPSIES AT PENN



## STOOL SAMPLES OUR LONG COVID COHORT



# SARS-COV-2 AND GASTROINTESTINAL TRACT

## MODELING INFECTION

- CULTURED CELLS
- ORGANOID MODELS


## ANTIVIRALS ACTIVE?

- KNOWN AND IN TRIALS
- AGAINST VARIANTS?

## RESPONSES TO INFECTION?


- PERSISTENT?
- INNATE IMMUNE ROLE

Caco-2 cells  
Polarized monolayer




EpiIntestinalFT



Villi Structures -  
Columnar Epithelium (K19, red) -  
Lamina Propria Fibroblasts -  
(Vimentin, green)




# ARE THERE DIFFERENCES IN ANTIVIRAL ACTIVITY?




CALU-3




CACO-2



### Interferon $\beta$





### Molnupiravir



- Total cells
- % Infection





# WE CAN MODEL INFECTION IN 3D CULTURES




# WE SEE DIFFERENT SENSITIVITIES

## BRONCHIAL CULTURES

## INTESTINAL CULTURES



# CAN WE DETERMINE EFFECTIVE TREATMENT SCHEDULE ADMINISTERED SINGLE DOSE....



# PASC AND THE GASTROINTESTINAL TRACT

## IS THE GI TRACT A RESERVIOR?

- FOR WHICH PATIENTS?
- WHERE IS THE VIRUS?
- IS IT REPLICATING?

## ANTIVIRALS ACTIVE IN GI?

- WHICH ANTIVIRALS MOST ACTIVE
- HOW LONG TO TREAT?
- WHAT COMBINATIONS

## RESPONSES TO INFECTION?

- WHAT ARE THE CELLULAR RESPONSES?
- CAN WE REDIRECT?

# ACKNOWLEDGEMENTS

## Cherry Lab:

Benjamin Gabriel  
Jesse Hulahan  
Alex Huber  
Max Ferretti  
Kasirajan Ayyanathan  
Mark Dittmar  
Trevor Greisman  
Iulia Tapescu  
Rachel Braun  
Jorge Acuna  
Kaeri Martinez  
Tamanna Srivastava  
Jae Seung Lee  
Zienab Etwebi  
Steven Miller  
Priyanka Bhakt  
Jesse Miller  
Beth Gold  
Swechha Pokherel  
Megha Basavappa\*  
Minghua Li\*

## HTS Core:

David Schultz  
Kanupriya Whig  
David Nguyen  
Emilia Roberts  
Christina Freeman  
Hongzhuang Peng  
Yongqing Zhu

## Animal Studies:

Michael Diamond (Wash U)  
Matthew Frieman (UMD)  
Kellie Jurado

## PATH Lab:

Micheal Feldman  
Kathleen Montone



Marc Ferrer, Emily Lee  
J. Shrimp, M. Hall

Medicines for Malaria Venture

Kirandeep Samby, Timothy Wells

Gates Foundation

Monalisa Chatterji, Rob Jordan, Ken Duncan

Calibr The Calibr logo, which includes the word "Calibr" and a stylized infinity symbol.

Biorender



Ann Eakin, Mindy Davis



## Collaborations:

Christoph Thaiss  
Maayan Levy  
Benjamin Abramoff  
Kristen Lynch

## Cell Models:

MatTek, Epithelix, iPSC Core

## Metabolomics:

Chris Petucci, WISTAR



## Funding:

NIH, Gates Foundation, BWF, Mercatus Fast Grant, Linda and Laddie Montague, Deans Innovation Fund, Penn Center for Precision Medicine, PolyBio Research